Mahesh patel lipocine
WebNov 18, 2024 · Mahesh V. Patel has not been actively trading shares of Lipocine over the course of the past ninety days. Most recently, on Friday, March 24th, Mahesh V. Patel bought 150,000 shares of Lipocine stock. … WebSep 30, 2024 · Our initial focus is on endogenous neuroactive steroids which have broad applicability in treating various CNS conditions," said Dr. Mahesh Patel, President and …
Mahesh patel lipocine
Did you know?
WebJan 12, 2024 · "We are pleased by the top-line results from our LiFT study, which we believe demonstrate the potential for oral LPCN 1144's to be used in treating NASH," said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine Inc. "Additionally, NASH patients are likely to have compromised androgen signaling with associated sarcopenia, skeletal ... WebOct 18, 2024 · Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to …
WebMar 20, 2024 · CEO and President Mahesh Patel acquired a total of 50,000 shares at an average price of $0.33. To acquire these shares, it cost around $16.5 thousand. What’s Happening: Lipocine posted... WebDec 9, 2024 · Commenting on the FDA approval of Tlando, Mahesh Patel, Chairman, President and Chief Executive Officer of Lipocine, said, "We believe that TLANDO represents a differentiated TRT for treating...
WebSep 15, 2024 · "We are truly excited about the encouraging FDA pathway feedback and oral enablement of brexanolone through leveraging of our proprietary Lip'ral technology … WebAug 25, 2024 · Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107.
WebDr. Mahesh V. Patel has more than 20 years of technology and product development experience in the area of drug discovery support, drug delivery and product line …
WebApr 3, 2024 · The study is expected to enroll a total of 12 participants and is being conducted at a single center in the US. Results are expected in the first half of 2024. "We are excited about our development progress for LPCN 1154," said Dr. Mahesh Patel, President and CEO of Lipocine Inc. eval function in c++WebDr. Mahesh Patel is a surgical oncologist specializing in the Abdomen and Thoracic cancer. Abdomen orGastro-Intestinal (GI) cancer is a term for the group of cancers that affect the … first baptist preschool covington laWebApr 3, 2024 · About Lipocine Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to … eval function in reactWebThe Orthopedic and Sports Medicine team at Watertown Regional Medical Center is led by board-certified and fellowship trained surgeons offering state-of-the-art technology and … first baptist preschool amarillo txWebDec 23, 2024 · On average, Lipocine Inc executives and independent directors trade stock every 73 days with the average trade being worth of $12,374. The most recent stock trade was executed by Mahesh V. Patel on 24 March 2024, trading 150,000 units of LPCN stock currently worth $48,000. eval function in cppWebSummary Presently, Mahesh V. Patel is President, Chief Executive & Financial Officer at Lipocine, Inc. He received an undergraduate degree from Karnataka University, a graduate degree from the University of Cincinnati (Ohio) and a doctorate from the University of Utah. Current positions of Mahesh V. Patel Holdings of Mahesh V. Patel first baptist preschool lexington ncWebNov 9, 2024 · Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous... eval function in ibm